Publications

Devastating neurologic consequences of localized scleroderma en coup de sabre of the scalp-2 case studies.

Ma C, Legault K, Provias J, Zhang E, Gallienne C, Larche M.J Scleroderma Relat Disord. 2025 Jun 1;10(3):NP5-NP9. doi: 10.1177/23971983251342687. eCollection 2025 Oct.PMID: 40470115

Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies.

Barreth N, Leclair V, Hudson M, Bernatsky S, Krustev E, Moran Toro C, St Pierre Y, Clarke A, Sciore PJA, Tarnopolsky M, Fritzler MJ, Choi MY; Canadian Inflammatory Myopathy Study.Rheumatology (Oxford). 2026 Apr 6;65(4):keag139. doi: 10.1093/rheumatology/keag139.PMID: 41872012

A qualitative study of the impact of the COVID-19 pandemic on healthcare access and service delivery for people living with chronic obstructive pulmonary disease and asthma.

Brehon K, Choi M, Hung P, Miciak M, Lim RK, Bhutani M, Perreault K, Ronksley PE, Stickland MK, Weatherald J, Gross DP, Lam GY.Allergy Asthma Clin Immunol. 2026 Jun 26. doi: 10.1186/s13223-026-01052-y. Online ahead of print.PMID: 42363213

Characterization of Incident Interstitial Lung Disease in Late Systemic Sclerosis.

Hoa S, Berger C, Lahmek N, Larché M, Osman M, Choi M, Pope J, Thorne C; Canadian Scleroderma Research Group; Hudson M.Arthritis Rheumatol. 2025 Apr;77(4):450-457. doi: 10.1002/art.43051. Epub 2025 Jan 7.PMID: 39492683

Anti-TRIM72 Autoantibodies in Idiopathic Inflammatory Myopathies.

Krustev E, Safaei TN, Trejo-Zambrano D, Christopher-Stine L, Mammen A, Paik JJ, Albayda J, Mecoli CA, Adler BL, Weisleder N, Jarjour W, Antiochos B, Tiniakou E.medRxiv [Preprint]. 2025 Jul 24:2025.07.23.25332079. doi: 10.1101/2025.07.23.25332079.PMID: 40778135